A Double-blind Randomized Single-center Trial of Basiliximab for the Treatment of Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Resolution of GVHD by Day 12
Lawrence SY Ma, Dr
Department of Medicine/ Haematology and Oncology, Queen Mary Hospital
Hong Kong: Ethics Committee
UW 03-312 T312